Loading...
Indian Pharmaceutical Exporter · Respiratory Specialist · $2.5M Total Trade · DGFT Verified
Vamsi Pharma Private Limited is an Indian pharmaceutical exporter with a total trade value of $2.5M across 3 products in 1 therapeutic categories. Based on 49 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Fluticasone ($900.0K), Salmeterol ($900.0K), Tiotropium ($650.0K).
Vamsi Pharma Private Limited, established on July 16, 2015, is a private pharmaceutical company headquartered in Hyderabad, Telangana, India. The company specializes in the development and manufacturing of orally inhaled and nasal drug products (OINDP), with a particular emphasis on Dry Powder Inhalers (DPI). Operating under Corporate Identification Number (CIN) U24100TG2015PTC099814, Vamsi Pharma is classified as a private limited company. The authorized capital stands at ₹17.50 crore, with a paid-up capital of ₹15.63 crore. As of April 8, 2024, the company employed 32 professionals. The registered office is located at Sy. No. 707 & 708, Nandi Gama Village, Mekagudem GP, Kothur Mandal, Hyderabad, Telangana, 509228.
Vamsi Pharma Private Limited operates across 1 therapeutic categories, with Respiratory (100.0%), representing the largest segments by export value. The portfolio is concentrated — the top 5 products account for 100% of total exports.
Respiratory
3 products · 100.0% · $2.5M
Vamsi Pharma Private Limited exports 3 pharmaceutical products across 1 therapeutic categories.
| # | Product | Category | Export Value | Shipments | Market Share | Rank |
|---|---|---|---|---|---|---|
| 1 | Fluticasone | Respiratory | $900.0K | 18 | 0.4% |
Headquarters, ownership, manufacturing facilities, and key leadership
Vamsi Pharma Private Limited, established on July 16, 2015, is a private pharmaceutical company headquartered in Hyderabad, Telangana, India. The company specializes in the development and manufacturing of orally inhaled and nasal drug products (OINDP), with a particular emphasis on Dry Powder Inhalers (DPI). Operating under Corporate Identification Number (CIN) U24100TG2015PTC099814, Vamsi Pharma is classified as a private limited company. The authorized capital stands at ₹17.50 crore, with a paid-up capital of ₹15.63 crore. As of April 8, 2024, the company employed 32 professionals. The registered office is located at Sy. No. 707 & 708, Nandi Gama Village, Mekagudem GP, Kothur Mandal, Hyderabad, Telangana, 509228.
Vamsi Pharma operates a WHO-GMP certified manufacturing facility situated in Hyderabad, Telangana, India. The plant specializes in the production of orally inhaled and nasal drug products, focusing on Dry Powder Inhalers (DPI). The facility is equipped to handle the entire product development lifecycle, from ideation and research to formulation, regulatory compliance, scale-up, and market launch.
| 6 |
| 2 | Salmeterol | Respiratory | $900.0K | 18 | 1.2% | 5 |
| 3 | Tiotropium | Respiratory | $650.0K | 13 | 1.0% | 3 |
Vamsi Pharma Private Limited exports 3 pharmaceutical products across 1 therapeutic categories with a total export value of $2.5M. The top category is Respiratory (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.
Shipment-level records, pricing & buyer contacts for Vamsi Pharma Private Limited.
Request DemoThe leadership team at Vamsi Pharma comprises several key individuals:
The company secretary is Venkatachalam Seetharaman, appointed on September 21, 2024.
Regulated market presence, emerging market penetration, and geographic strategy
Vamsi Pharma's export activities, as per TransData Nexus proprietary trade data from 2022 to 2026, indicate a total export value of $2.5 million USD across 49 shipments, primarily in the respiratory therapeutic category. The top three exported products are Fluticasone ($900K), Salmeterol ($900K), and Tiotropium ($650K). These products are finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's portfolio is highly concentrated, with the top five products accounting for 100% of exports. Notably, Salmeterol holds a 1.2% market share, ranking fifth, while Tiotropium holds a 1.0% market share, ranking third. The company's focus on respiratory products aligns with global health priorities, particularly in managing asthma and chronic obstructive pulmonary disease (COPD).
Vamsi Pharma's export data indicates a concentration in the respiratory therapeutic category, with no diversification into other therapeutic areas. This focus suggests a strategic emphasis on respiratory treatments, potentially limiting exposure to market fluctuations in other therapeutic segments. The company's export activities are primarily directed towards markets with established demand for respiratory medications, which may include regions in Africa, Latin America, and Southeast Asia. However, specific market penetration details are not available in the provided data.
Vamsi Pharma's export strategy is highly concentrated, with the top five products accounting for 100% of exports. This indicates a focused approach on a limited product range, which can lead to increased vulnerability to market fluctuations and regulatory changes affecting these specific products. The company's strategic direction appears to be centered on respiratory treatments, leveraging its expertise in this therapeutic area. While this focus allows for specialization, it may also pose risks associated with market concentration.
FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record
Specific details regarding Vamsi Pharma's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not available in the provided data. Given the company's focus on respiratory products, it is plausible that they have pursued regulatory approvals in markets such as the United States. However, without explicit information, a comprehensive assessment of their FDA status cannot be made.
Vamsi Pharma's manufacturing facility is WHO-GMP certified, indicating compliance with the World Health Organization's Good Manufacturing Practices. This certification underscores the company's commitment to maintaining high-quality standards in its production processes. Specific details regarding EU GMP certificates or EDQM status are not available in the provided data.
Vamsi Pharma holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. The company's facility is located in Hyderabad, Telangana, and is registered under the jurisdiction of the Hyderabad Regional Office of the CDSCO. Specific details regarding state drug controller approvals and export No Objection Certificates (NOCs) are not available in the provided data.
No specific information regarding Form 483 observations, warning letters, or import alerts related to Vamsi Pharma is available in the provided data. The absence of such information suggests that the company may not have faced significant regulatory challenges in recent years.
Market share comparison, key differentiators, and strategic analysis
Vamsi Pharma operates in the respiratory therapeutic category, exporting products such as Fluticasone, Salmeterol, and Tiotropium. The company's portfolio is highly concentrated, with the top five products accounting for 100% of exports. While specific market share data for competitors is not available, the respiratory market is competitive, with several established players offering similar products. Vamsi Pharma's focus on respiratory treatments positions it within a niche segment, potentially reducing direct competition but also limiting market opportunities.
Vamsi Pharma's key differentiators include its specialized focus on respiratory treatments, particularly in the development and manufacturing of Dry Powder Inhalers (DPI). The company's WHO-GMP certified facility and its "Concept to Commissioning" model for product development highlight its commitment to quality and comprehensive service offerings. This integrated approach allows Vamsi Pharma to deliver innovative and cost-effective inhalation products, catering to the evolving demands of global healthcare markets.
Vamsi Pharma's strategic direction is centered on the development and manufacturing of respiratory treatments, with a particular emphasis on Dry Powder Inhalers (DPI). The company's focus on this niche segment allows for specialization and expertise in pulmonary drug delivery technologies. While this concentrated approach may limit exposure to other therapeutic areas, it also positions Vamsi Pharma as a specialized player in the respiratory market, potentially offering unique value propositions to partners and clients.
Track record assessment, certifications to verify, and pre-order checks
Vamsi Pharma's export data indicates a total export value of $2.5 million USD across 49 shipments, primarily in the respiratory therapeutic category. The company's portfolio is highly concentrated, with the top five products accounting for 100% of exports. This suggests a focused approach on a limited product range, which can lead to increased vulnerability to market fluctuations and regulatory changes affecting these specific products. The company's WHO-GMP certified facility and its "Concept to Commissioning" model for product development highlight its commitment to quality and comprehensive service offerings. However, the lack of diversification in its product portfolio may pose risks associated with market concentration.
Importers should verify the following certifications to ensure product quality and regulatory compliance:
Importers should undertake the following steps to ensure due diligence:
Vamsi Pharma Private Limited exports 3 pharmaceutical products across 1 therapeutic categories. The top exports are Fluticasone ($900.0K), Salmeterol ($900.0K), Tiotropium ($650.0K). Total export value is $2.5M.
Vamsi Pharma Private Limited's total pharmaceutical export value is $2.5M, based on 49 verified shipments recorded in Indian Customs (DGFT) data.
Vamsi Pharma Private Limited exports across 1 therapeutic categories. The largest are Respiratory (100.0%, 3 products).
Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Verify manufacturer licensing, GMP certification, and export registration with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
3 Products Tracked
1 therapeutic categories
Expert-Reviewed
By pharmaceutical trade specialists
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.